[go: up one dir, main page]

EP0975339A1 - Pharmaceutical composition for the programmed release of dexfenfluramine - Google Patents

Pharmaceutical composition for the programmed release of dexfenfluramine

Info

Publication number
EP0975339A1
EP0975339A1 EP98912553A EP98912553A EP0975339A1 EP 0975339 A1 EP0975339 A1 EP 0975339A1 EP 98912553 A EP98912553 A EP 98912553A EP 98912553 A EP98912553 A EP 98912553A EP 0975339 A1 EP0975339 A1 EP 0975339A1
Authority
EP
European Patent Office
Prior art keywords
minigranules
release
pharmaceutical composition
composition according
slow
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98912553A
Other languages
German (de)
French (fr)
Inventor
Bruno Huet De Barochez
Claude Dauphant
Patrick Wuthrich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoires Servier SAS
Original Assignee
ADIR SARL
Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ADIR SARL, Laboratoires Servier SAS filed Critical ADIR SARL
Publication of EP0975339A1 publication Critical patent/EP0975339A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Definitions

  • the present invention relates to a pharmaceutical composition for the programmed release of dexfenfiuramine by the oral route.
  • Dexfenfiuramine is an active ingredient used in the treatment of obesity.
  • This active ingredient has so far been administered orally, twice a day, in the form of an immediate-release capsule, dosed at 15 mg dexfenfiuramine hydrochloride.
  • the Applicant has currently developed an extended-release form of dexfenfiuramine which has the advantage for the patient of being administered only once a day.
  • the new pharmaceutical composition which is the subject of the present invention has the advantage not only of prolonging the release of the active ingredient. but still to delay this release. This makes it possible to modulate the release of the active principle as a function of the hours of the day and thus to obtain two peaks of plasma concentration, which, depending on the percentage of the constituents of this pharmaceutical composition, can be adapted to the requirements of the treatment.
  • the active principle is administered chronobiologically: a first part of the active principle is released instantly, the other part is released after a few hours, which makes it possible to obtain two peaks of plasma concentration staggered in the time.
  • the pharmaceutical composition according to the invention consists of: - quick-release minigranules, - slow-release minigranules. All of these minigranules are then put in a pharmaceutically acceptable form.
  • These pharmaceutically acceptable forms are preferably capsules or tablets.
  • the quick-release minigranules consist of neutral supports on which the active principle is deposited. These minigranules can then optionally be coated with a polymer allowing rapid release of the active principle.
  • the slow-release minigranules consist of neutral supports on which the active principle and talc are deposited. These minigranules are then coated with a polymer allowing the release of the active principle to be controlled and with a surfactant. This coating may also contain other excipients such as plasticizers or stabilizing agents.
  • the neutral supports used in the minigranules are more particularly neutral microgranules and preferably of sucrose-starch microgranules.
  • binders can be used such as, for example, methylhydroxypropylcellulose.
  • the preferred polymer is a low viscosity methyl hydroxypropyl cellulose.
  • water-insoluble cellulose derivatives such as, for example, ethylcellulose or cellulose acetate or acrylic copolymers such as Eudragits.
  • the preferred polymer is ethylcellulose.
  • the surfactants used for coating the slow-release minigranules there may be mentioned the fatty alcohol ester salts or the polysorbates.
  • the preferred surfactant is sodium lauryl sulfate.
  • the plasticizers optionally used for coating the slow-release minigranules there may be mentioned the esters of citric acid or the sebacates.
  • the preferred plasticizer is acetyltributylcitrate.
  • stabilizing agents optionally used for coating the slow-release minigranules, mention may preferably be made of cetyl alcohol.
  • minigranules can also contain excipients conventionally used as colorants, flavoring agents, bulking agents ... and can contain anti-sticking agents making it possible to avoid sticking of the minigranules together when their preparation.
  • Slow or fast minigranules are produced either by extrusion and spheronization, whether or not followed by coating, or by assembly and coating.
  • the preferred manufacturing process for these minigranules is mounting followed by coating.
  • the rapid minigranules are prepared by mounting, that is to say by spraying an aqueous solution of the active principle which can contain a binder, for example methyl hydroxypropylcellulose, on a neutral support, for example neutral sucrose-starch microgranules.
  • the minigranules are dried as they are assembled, either by using a coating or film-coating turbine equipped with a blower and a hot air suction, or by using a fluidized air bed apparatus.
  • a protective coating is optionally applied, using the same equipment.
  • the polymer used to protect the minigranules must allow rapid release of the active principle.
  • Slow minigranules are prepared according to the same mounting principle, talc being added to the mounting solution.
  • the coating of these minigranules is applied using the same apparatus.
  • talc in the mounting suspension as well as the use of a surfactant such as sodium lauryl sulfate made it possible to obtain a delayed release of the active principle. This release can be delayed by 4 hours or more and modulated over time depending on the percentages of constituents used. Rapid minigranules contain 10 to 80% dexfenfiuramine. Slow minigranules contain 10 to 80% dexfenfiuramine. The percentage of talc contained in the slow-release minigranules is between 10 and 80% of the mass of active principle.
  • the percentage of surfactant contained in the slow-release minigranules is between 0.05% and 3% of the total mass of the minigranules before coating.
  • the percentage of the polymer used for coating the slow-release minigranules is between 3 and 20% of the total mass of the minigranules before coating.
  • a suspension of active ingredient is sprayed onto neutral sucrose-starch microgranules (Micro granules 710-850 ⁇ m).
  • the suspension contains methylhydroxypropylcellulose in an amount of 2% relative to the amount of active ingredient and of talc, in an amount of 40% relative to the amount of active ingredient.
  • the assembly is carried out in a fluidized air bed.
  • a 5% (m / v) solution of ethylcellulose in alcohol is then sprayed onto the minigranules loaded with active ingredient.
  • This solution contains acetyltributyl citrate at a rate of 10% of the mass of ethylcellulose, sodium lauryl sulfate at a rate of 0.3% (m / v) and cetyl alcohol at a rate of 0.7% (m / v).
  • the coating is carried out in the same device as during assembly.
  • the kinetics of release of the active principle is measured using the rotary vane technique described in the European Pharmacopoeia.
  • the flasks are filled with 500 ml of phosphate buffer maintained at 37 ° C. The speed of the blades is 50 rpm.
  • the coating is carried out so as to obtain a coating containing 7, 8, 9 and 10% of ethylcellulose, percentage expressed relative to the mass of minigranules mounted.
  • the release kinetics obtained are shown in Figure 1 (in the appendix). A standby time of 2 to 4 hours is observed depending on the amount of polymer sprayed.
  • the minigranules described in this example were prepared according to the method described in Example 1 but do not contain talc.
  • the coatings correspond to amounts of ethylcellulose of 9, 12 and 14% of ethylcellulose.
  • the release kinetics obtained are shown in Figure 2 (in the appendix).
  • Minigranules mounted with talc are coated with an ethylcellulose solution containing acetyltributylcitrate without sodium lauryl sulfate.
  • the quantity of ethylcellulose sprayed corresponds for each test to 9%.
  • the results are presented in FIG. 3 (in the appendix), compared to the corresponding formula of example 1 and to that corresponding of example 2 (without talc). It appears that a combination of talc in the mounting suspension and sodium lauryl sulfate in the coating solution is required to obtain a latency of at least 2 h.
  • a suspension of active ingredient is sprayed onto neutral sucrose-starch microgranules.
  • the suspension contains methylhydroxypropylcellulose at a rate of 2% relative to the amount of active ingredient.
  • a 5% solution (m / v) of methylhydroxypropylcellulose in alcohol is then sprayed onto the minigranules loaded with active ingredient.
  • the coating is carried out in the same device as the assembly.
  • capsules containing quick-release minigranules and slow-release minigranules are examples of capsules containing quick-release minigranules and slow-release minigranules.
  • Formulation A contains two types of minigranules: rapid release minigranules obtained according to the process described in Example 4. These minigranules are coated with a standard suspension of methyl hydroxypropylcellulose containing a red dye. Slow-release minigranules obtained according to the process described in Example 1 but do not containing neither talc, nor ethyl alcohol, nor sodium lauryl sulphate and with an amount of ethyl cellulose of 9%. The quantities of these minigranules are such that they make it possible to obtain 10 mg of dexfenfiuramine released immediately and 20 mg of dexfenfiuramine released in a delayed or prolonged manner. These slow and fast minigranules are put in capsules.
  • Formulation B is identical to formulation A but the slow release minigranules contain talc, ethyl alcohol and sodium lauryl sulfate.
  • Figure 4 presented in the appendix compares the kinetics of dissolution of the two formulations. There is a plateau on the profile of formulation B, plateau corresponding to the latency time of the minigranules with sustained release. Formulation A does not present this plateau.
  • These capsules were used for a pharmacokinetic study comparing the capsules of formulation A and B with an immediate-release formulation dosed at 15 mg of active principle in 9 healthy male volunteers. The plasma concentrations obtained are shown in FIG. 5.
  • the profile of formulation B shows two peaks of plasma concentration; the first corresponds to the Cmax of the immediate release form (2.5 to 3 h), the other is around 8 h.
  • Formulation C is identical to formulation B but the immediate-release minigranules are coated with a dye-free suspension of hydroxypropylmethylcellulose.
  • the unit formula of formulation C is presented in the following table:

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention concerns a novel pharmaceutical composition for the programmed release of dexfenfluramine characterised in that it contains a mixture of microgranules as defined in the description. The invention is useful for preparing medicines.

Description

COMPOSITION PHARMACEUTIQUE POUR LA LffiERATION PROGRAMMEE DE DEXFENFLURAMINE PHARMACEUTICAL COMPOSITION FOR THE PROGRAMMED LffiERATION OF DEXFENFLURAMINE
La présente invention a pour objet une composition pharmaceutique pour la libération programmée de dexfenfiuramine par voie orale.The present invention relates to a pharmaceutical composition for the programmed release of dexfenfiuramine by the oral route.
La dexfenfiuramine est un principe actif utilisé dans le traitement de l'obésité.Dexfenfiuramine is an active ingredient used in the treatment of obesity.
Ce principe actif est jusqu'à présent administré, par voie orale, deux fois par jour, sous la forme d'une gélule à libération immédiate, dosée à 15 mg de chlorhydrate de dexfenfiuramine.This active ingredient has so far been administered orally, twice a day, in the form of an immediate-release capsule, dosed at 15 mg dexfenfiuramine hydrochloride.
La demanderesse a présentement mis au point une forme à libération prolongée de dexfenfiuramine présentant l'avantage pour le malade de n'être administrée qu'une seule fois par jour.The Applicant has currently developed an extended-release form of dexfenfiuramine which has the advantage for the patient of being administered only once a day.
D'autre part, alors que la plupart des formes à libération prolongée permettent uniquement de prolonger dans le temps la libération du principe actif, la nouvelle composition pharmaceutique, objet de la présente invention présente l'avantage non seulement de prolonger la libération du principe actif mais encore de retarder cette libération. Ceci permet de moduler la libération du principe actif en fonction des heures de la journée et ainsi d'obtenir deux pics de concentration plasmatique, qui, en fonction du pourcentage des constituants de cette composition pharmaceutique, peuvent être adaptés aux exigences du traitement.On the other hand, while most of the sustained-release forms only allow the release of the active ingredient to be prolonged over time, the new pharmaceutical composition which is the subject of the present invention has the advantage not only of prolonging the release of the active ingredient. but still to delay this release. This makes it possible to modulate the release of the active principle as a function of the hours of the day and thus to obtain two peaks of plasma concentration, which, depending on the percentage of the constituents of this pharmaceutical composition, can be adapted to the requirements of the treatment.
Enfin, cette nouvelle forme pharmaceutique s'adapte parfaitement aux caractéristiques physicochimiques de la dexfenfiuramine.Finally, this new pharmaceutical form adapts perfectly to the physicochemical characteristics of dexfenfiuramine.
Dans cette nouvelle forme pharmaceutique, le principe actif est administré de manière chronobiologique : une première partie du principe actif est libérée instantanément, l'autre partie est libérée au bout de quelques heures ce qui permet d'obtenir deux pics de concentration plasmatique échelonnés dans le temps.In this new pharmaceutical form, the active principle is administered chronobiologically: a first part of the active principle is released instantly, the other part is released after a few hours, which makes it possible to obtain two peaks of plasma concentration staggered in the time.
La composition pharmaceutique selon l'invention est constituée par : - des minigranules à libération rapide, - des minigranules à libération lente. L'ensemble de ces minigranules est alors mis sous une forme pharmaceutiquement acceptable.The pharmaceutical composition according to the invention consists of: - quick-release minigranules, - slow-release minigranules. All of these minigranules are then put in a pharmaceutically acceptable form.
Ces formes pharmaceutiquement acceptables sont préférentiellement les gélules ou les comprimés.These pharmaceutically acceptable forms are preferably capsules or tablets.
Les minigranules à libération rapide sont constitués de supports neutres sur lesquels le principe actif est déposé. Ces minigranules peuvent alors être éventuellement enrobés par un polymère permettant une libération rapide du principe actif.The quick-release minigranules consist of neutral supports on which the active principle is deposited. These minigranules can then optionally be coated with a polymer allowing rapid release of the active principle.
Les minigranules à libération lente sont constitués de supports neutres sur lesquels le principe actif et de talc sont déposés. Ces minigranules sont alors enrobés par un polymère permettant le contrôle de la libération du principe actif et par un agent tensioactif . Cet enrobage peut également contenir d'autres excipients comme des plastifiants ou des agents stabilisants.The slow-release minigranules consist of neutral supports on which the active principle and talc are deposited. These minigranules are then coated with a polymer allowing the release of the active principle to be controlled and with a surfactant. This coating may also contain other excipients such as plasticizers or stabilizing agents.
Les supports neutres utilisés dans les minigranules sont plus particulièrement des microgranules neutres et préférentiellement de microgranules saccharose-amidon.The neutral supports used in the minigranules are more particularly neutral microgranules and preferably of sucrose-starch microgranules.
Afin de mieux fixer le principe actif sur ces supports neutres, divers liants peuvent être utilisés comme par exemple la méthylhydroxypropylcellulose.In order to better fix the active principle on these neutral supports, various binders can be used such as, for example, methylhydroxypropylcellulose.
Parmi les polymères utilisés éventuellement pour l'enrobage des minigranules à libération rapide, on peut citer les polymères cellulosiques permettant une libération rapide du principe actif. Le polymère préféré est une méthylhydroxypropylcellulose de faible viscosité.Among the polymers optionally used for coating the quick-release minigranules, mention may be made of cellulosic polymers allowing rapid release of the active principle. The preferred polymer is a low viscosity methyl hydroxypropyl cellulose.
Parmi les polymères utilisés pour l'enrobage des minigranules à libération lente, on peut citer les dérivés de cellulose insolubles dans l'eau comme par exemple l'éthylcellulose ou l'acétate de cellulose ou des copolymeres acryliques comme les Eudragit . Le polymère préféré est l'éthylcellulose.Among the polymers used for coating the slow-release minigranules, mention may be made of water-insoluble cellulose derivatives such as, for example, ethylcellulose or cellulose acetate or acrylic copolymers such as Eudragits. The preferred polymer is ethylcellulose.
Parmi les agents tensioactifs utilisés pour l'enrobage des minigranules à libération lente, on peut citer les sels d'esters d'alcool gras ou les polysorbates. L'agent tensioactif préféré est le laurylsulfate de sodium. Parmi les plastifiants utilisés éventuellement pour l'enrobage des minigranules à libération lente, on peut citer les esters de l'acide citrique ou les sébaçates. Le plastifiant préféré est 1 ' acétyltributylcitrate.Among the surfactants used for coating the slow-release minigranules, there may be mentioned the fatty alcohol ester salts or the polysorbates. The preferred surfactant is sodium lauryl sulfate. Among the plasticizers optionally used for coating the slow-release minigranules, there may be mentioned the esters of citric acid or the sebacates. The preferred plasticizer is acetyltributylcitrate.
Parmi les agents stabilisants utilisés éventuellement pour l'enrobage des minigranules à libération lente, on peut citer préférentiellement l'alcool cétylique.Among the stabilizing agents optionally used for coating the slow-release minigranules, mention may preferably be made of cetyl alcohol.
Enfin, ces deux types de minigranules peuvent également contenir des excipients classiquement utilisés comme des colorants, des agents de saveurs, des agents de charges... et peuvent contenir des agents anti-collage permettant d'éviter le collage des minigranules entre eux lors de leur préparation.Finally, these two types of minigranules can also contain excipients conventionally used as colorants, flavoring agents, bulking agents ... and can contain anti-sticking agents making it possible to avoid sticking of the minigranules together when their preparation.
Les minigranules lents ou rapides sont fabriqués soit par extrusion et sphéronisation suivi ou non d'un enrobage, soit par montage et enrobage. Le procédé de fabrication préféré de ces minigranules est le montage suivi de l'enrobage.Slow or fast minigranules are produced either by extrusion and spheronization, whether or not followed by coating, or by assembly and coating. The preferred manufacturing process for these minigranules is mounting followed by coating.
Les minigranules rapides sont préparés par montage, c'est-à-dire par pulvérisation d'une solution aqueuse du principe actif pouvant renfermer un liant, par exemple la méthylhydroxypropylcellulose, sur un support neutre, par exemple des microgranules neutres saccharose-amidon. Les minigranules sont séchés au fur et à mesure du montage, soit en utilisant une turbine de dragéification ou de pelliculage munie d'une soufflerie et d'une aspiration d'air chaud, soit en utilisant un appareil à lit d'air fluidisé. Une fois le principe actif déposé sur les supports neutres, un enrobage de protection est éventuellement appliqué, en utilisant le même appareillage. Le polymère utilisé pour protéger les minigranules doit permettre une rapide libération du principe actif.The rapid minigranules are prepared by mounting, that is to say by spraying an aqueous solution of the active principle which can contain a binder, for example methyl hydroxypropylcellulose, on a neutral support, for example neutral sucrose-starch microgranules. The minigranules are dried as they are assembled, either by using a coating or film-coating turbine equipped with a blower and a hot air suction, or by using a fluidized air bed apparatus. Once the active principle has been deposited on neutral supports, a protective coating is optionally applied, using the same equipment. The polymer used to protect the minigranules must allow rapid release of the active principle.
Les minigranules lents sont préparés selon le même principe de montage, le talc étant ajouté à la solution de montage. L'enrobage de ces minigranules est appliqué en utilisant le même appareillage.Slow minigranules are prepared according to the same mounting principle, talc being added to the mounting solution. The coating of these minigranules is applied using the same apparatus.
II a été montré que l'utilisation du talc dans la suspension de montage ainsi que l'utilisation d'un agent tensioactif comme le laurylsulfate de sodium permettait d'obtenir une libération retardée du principe actif. Cette libération peut être retardée de 4 heures ou plus et modulée dans le temps en fonction des pourcentages de constituants utilisés. Les minigranules rapides contiennent de 10 à 80 % de dexfenfiuramine. Les minigranules lents contiennent de 10 à 80 % de dexfenfiuramine. Le pourcentage de talc contenu dans les minigranules à libération lente est compris entre 10 et 80 % de la masse de principe actif.It has been shown that the use of talc in the mounting suspension as well as the use of a surfactant such as sodium lauryl sulfate made it possible to obtain a delayed release of the active principle. This release can be delayed by 4 hours or more and modulated over time depending on the percentages of constituents used. Rapid minigranules contain 10 to 80% dexfenfiuramine. Slow minigranules contain 10 to 80% dexfenfiuramine. The percentage of talc contained in the slow-release minigranules is between 10 and 80% of the mass of active principle.
Le pourcentage d'agent tensioactif contenu dans les minigranules à libération lente est compris entre 0,05 % et 3 % de la masse totale des minigranules avant enrobage. Le pourcentage du polymère utilisé pour l'enrobage des minigranules à libération lente est compris entre 3 et 20 % de la masse totale des minigranules avant enrobage.The percentage of surfactant contained in the slow-release minigranules is between 0.05% and 3% of the total mass of the minigranules before coating. The percentage of the polymer used for coating the slow-release minigranules is between 3 and 20% of the total mass of the minigranules before coating.
Les exemples suivants illustrent l'invention mais ne la limitent en aucune façon.The following examples illustrate the invention but do not limit it in any way.
Exemples de préparation de minigranules à libération prolongée et retardéeExamples of preparation of prolonged and delayed release minigranules
Exemple 1 :Example 1:
Une suspension de principe actif est pulvérisée sur des microgranules neutres saccharose-amidon (Micro granules 710-850 μm). La suspension renferme de la méthylhydroxypropylcellulose à raison de 2 % par rapport à la quantité de principe actif et du talc, à raison de 40 % par rapport à la quantité de principe actif. Le montage est effectué dans un lit d'air fluidisé. Une solution à 5 % (m/v) d'éthylcellulose dans l'alcool est ensuite pulvérisée sur les minigranules chargés en principe actif. Cette solution renferme de l'acétyltributylcitrate à raison de 10 % de la masse d'éthylcellulose, du laurylsulfate de sodium à raison de 0,3 % (m/v) et de l'alcool cétylique à raison de 0,7 % (m/v). L'enrobage est effectué dans le même appareil que lors du montage. La cinétique de libération du principe actif est mesurée au moyen de la technique à palettes tournantes décrite à la Pharmacopée Européenne. Les ballons sont remplis avec 500 ml de tampon phosphate maintenu à 37°C. La vitesse des pales est de 50 tr/min. L'enrobage est effectué de manière à obtenir un enrobage renfermant 7, 8, 9 et 10 % d'éthylcellulose, pourcentage exprimé par rapport à la masse de minigranules montés. La cinétique de libération obtenue est représentée sur la Figure 1 (en annexe). Un temps de latence de 2 à 4 heures est observé en fonction de la quantité de polymère pulvérisé.A suspension of active ingredient is sprayed onto neutral sucrose-starch microgranules (Micro granules 710-850 μm). The suspension contains methylhydroxypropylcellulose in an amount of 2% relative to the amount of active ingredient and of talc, in an amount of 40% relative to the amount of active ingredient. The assembly is carried out in a fluidized air bed. A 5% (m / v) solution of ethylcellulose in alcohol is then sprayed onto the minigranules loaded with active ingredient. This solution contains acetyltributyl citrate at a rate of 10% of the mass of ethylcellulose, sodium lauryl sulfate at a rate of 0.3% (m / v) and cetyl alcohol at a rate of 0.7% (m / v). The coating is carried out in the same device as during assembly. The kinetics of release of the active principle is measured using the rotary vane technique described in the European Pharmacopoeia. The flasks are filled with 500 ml of phosphate buffer maintained at 37 ° C. The speed of the blades is 50 rpm. The coating is carried out so as to obtain a coating containing 7, 8, 9 and 10% of ethylcellulose, percentage expressed relative to the mass of minigranules mounted. The release kinetics obtained are shown in Figure 1 (in the appendix). A standby time of 2 to 4 hours is observed depending on the amount of polymer sprayed.
Exemple 2 :Example 2:
Les minigranules décrits dans cet exemple ont été préparés selon le procédé décrit dans l'exemple 1 mais ne contiennent pas de talc. Les enrobages correspondent à des quantités d'éthylcellulose de 9, 12 et 14 % d'éthylcellulose. La cinétique de libération obtenue est représentée sur la Figure 2 (en annexe).The minigranules described in this example were prepared according to the method described in Example 1 but do not contain talc. The coatings correspond to amounts of ethylcellulose of 9, 12 and 14% of ethylcellulose. The release kinetics obtained are shown in Figure 2 (in the appendix).
Ces courbes montrent clairement qu'un temps de latence suffisant ne peut être obtenu que lorsque les minigranules contiennent du talc comme dans l'exemple 1.These curves clearly show that sufficient latency can only be obtained when the minigranules contain talc as in Example 1.
Exemple 3 :Example 3:
Des minigranules montés avec du talc, identiques à ceux décrits dans l'exemple 1, sont enrobés avec une solution d'éthylcellulose renfermant de l'acétyltributylcitrate sans laurylsulfate de sodium. La quantité d'éthylcellulose pulvérisée correspond pour chaque essai à 9 %. Les résultats sont présentés sur la Figure 3 (en annexe), comparativement à la formule correspondante de l'exemple 1 et à celle correspondante de l'exemple 2 (sans talc). Il apparaît qu'il faut une combinaison de talc dans la suspension de montage et de laurylsulfate de sodium dans la solution d'enrobage pour obtenir un temps de latence d'au moins 2 h.Minigranules mounted with talc, identical to those described in Example 1, are coated with an ethylcellulose solution containing acetyltributylcitrate without sodium lauryl sulfate. The quantity of ethylcellulose sprayed corresponds for each test to 9%. The results are presented in FIG. 3 (in the appendix), compared to the corresponding formula of example 1 and to that corresponding of example 2 (without talc). It appears that a combination of talc in the mounting suspension and sodium lauryl sulfate in the coating solution is required to obtain a latency of at least 2 h.
Exemple de préparation de minigranules à libération immédiateExample of preparation of immediate release minigranules
Exemple 4 :Example 4:
Une suspension de principe actif est pulvérisée sur des microgranules neutres saccharose- amidon. La suspension renferme de la méthylhydroxypropylcellulose à raison de 2 % par rapport à la quantité de principe actif. Une solution à 5 % (m/v) de méthylhydroxypropylcellulose dans l'alcool est ensuite pulvérisée sur les minigranules chargés en principe actif. L'enrobage est effectué dans le même appareil que le montage.A suspension of active ingredient is sprayed onto neutral sucrose-starch microgranules. The suspension contains methylhydroxypropylcellulose at a rate of 2% relative to the amount of active ingredient. A 5% solution (m / v) of methylhydroxypropylcellulose in alcohol is then sprayed onto the minigranules loaded with active ingredient. The coating is carried out in the same device as the assembly.
Exemples de gélules contenant des minigranules à libération rapide et des minigranules à libération lenteExamples of capsules containing quick-release minigranules and slow-release minigranules
Exemple : Formulation AExample: Formulation A
La formulation A renferme deux types de minigranules : des minigranules à libération rapide obtenus selon le procédé décrit dans l'exemple 4. Ces minigranules sont enrobés au moyen d'une suspension standard de méthylhydroxypropylcellulose contenant un colorant rouge. Des minigranules à libération lente obtenus selon le procédé décrit dans l'exemple 1 mais ne contenant ni talc, ni alcool céthylique, ni laurylsulfate de sodium et avec une quantité d'éthyl cellulose de 9 %. Les quantités de ces minigranules sont telles qu'elles permettent d'obtenir 10 mg de dexfenfiuramine libérés immédiatement et 20 mg de dexfenfiuramine libérés de manière retardée ou prolongée. Ces minigranules lents et rapides sont mis en gélules.Formulation A contains two types of minigranules: rapid release minigranules obtained according to the process described in Example 4. These minigranules are coated with a standard suspension of methyl hydroxypropylcellulose containing a red dye. Slow-release minigranules obtained according to the process described in Example 1 but do not containing neither talc, nor ethyl alcohol, nor sodium lauryl sulphate and with an amount of ethyl cellulose of 9%. The quantities of these minigranules are such that they make it possible to obtain 10 mg of dexfenfiuramine released immediately and 20 mg of dexfenfiuramine released in a delayed or prolonged manner. These slow and fast minigranules are put in capsules.
Exemple 6 : Formulation BExample 6: Formulation B
La formulation B est identique à la formulation A mais les minigranules à libération lente contiennent du talc, de l'alcool céthylique et du laurylsulfate de sodium.Formulation B is identical to formulation A but the slow release minigranules contain talc, ethyl alcohol and sodium lauryl sulfate.
Les formules unitaires des formulations A et B sont présentées dans le tableau suivant :The unit formulas of formulations A and B are presented in the following table:
La figure 4 présentée en annexe compare les cinétiques de dissolution des deux formulations. On note un plateau sur le profil de la formulation B, plateau correspondant au temps de latence des minigranules à libération prolongée. La formulation A ne présente pas ce plateau. Ces gélules ont été utilisées pour une étude pharmacocinétique comparant les gélules de formulation A et B à une formulation à libération immédiate dosée à 15 mg de principe actif chez 9 sujets sains mâles volontaires. Les concentrations plasmatiques obtenues sont représentées sur la figure 5. Le profil de la formulation B montre deux pics de concentration plasmatique ; le premier correspond aux Cmax de la forme à libération immédiate (2,5 à 3 h), l'autre se situe vers 8 h.Figure 4 presented in the appendix compares the kinetics of dissolution of the two formulations. There is a plateau on the profile of formulation B, plateau corresponding to the latency time of the minigranules with sustained release. Formulation A does not present this plateau. These capsules were used for a pharmacokinetic study comparing the capsules of formulation A and B with an immediate-release formulation dosed at 15 mg of active principle in 9 healthy male volunteers. The plasma concentrations obtained are shown in FIG. 5. The profile of formulation B shows two peaks of plasma concentration; the first corresponds to the Cmax of the immediate release form (2.5 to 3 h), the other is around 8 h.
Exemple 7 : Formulation CExample 7: Formulation C
La formulation C est identique à la formulation B mais les minigranules à libération immédiate sont enrobés au moyen d'une suspension d'hydroxypropylméthylcellulose sans colorant. La formule unitaire de la formulation C est présentée dans le tableau suivant :Formulation C is identical to formulation B but the immediate-release minigranules are coated with a dye-free suspension of hydroxypropylmethylcellulose. The unit formula of formulation C is presented in the following table:
Quantités (mg)Quantities (mg)
Constituants Minigranules Minigranules Formule à libération à libération globale rapide lenteConstituents Minigranules Minigranules Slow rapid release global release formula
Minigranules nusNaked minigranules
Dexfenfiuramine, Chlorhydrate 10 20 30Dexfenfiuramine, Hydrochloride 10 20 30
Méthylhydroxypropylcellulose 0.4 0.8 1.2Methylhydroxypropylcellulose 0.4 0.8 1.2
Microgranules neutres saccharose-amidon 56.267 37.867 94.134Sucrose-starch neutral microgranules 56,267 37,867 94,134
Talc 8 8Talc 8 8
Véhicule intermédiaire, eau purifiéeIntermediate vehicle, purified water
Enrobage à libération rapideQuick release coating
Méthylhydroxypropylcellulose Véhicule intermédiaire, eau purifiéeMethylhydroxypropylcellulose Intermediate vehicle, purified water
Enrobage à libération lenteSlow release coating
Acétyl tributyl citrate 0.6 0.6Acetyl tributyl citrate 0.6 0.6
Alcool cétylique 0.685 0.685Cetyl alcohol 0.685 0.685
Ethylcellulose 6 6Ethylcellulose 6 6
Lauryl sulfate de sodium 0.3 0.3Sodium lauryl sulfate 0.3 0.3
Véhicule intermédiaire : éthanolIntermediate vehicle: ethanol
Mise en géluleCapsule
Stéarate de magnésium 0.075 0.075 0.15Magnesium stearate 0.075 0.075 0.15
Pour une gélule blanc opaque remplie à 142.069 Le profil de libération in vitro est présenté sur la figure 6 en annexe. Il est identique au profil observé pour la formulation B : ce qui indique que la suspension colorante utilisée n'a pas d'influence sur le profil de libération de la dexfenfiuramine. Cette courbe montre bien un profil de libération prolongée de la dexfenfiuramine avec un palier obtenu pendant les 4 premières heures de libération du principe actif. For an opaque white capsule filled to 142,069 The in vitro release profile is presented in Figure 6 in the appendix. It is identical to the profile observed for formulation B: which indicates that the coloring suspension used has no influence on the release profile of dexfenfiuramine. This curve clearly shows a profile of prolonged release of dexfenfiuramine with a plateau obtained during the first 4 hours of release of the active principle.

Claims

REVENDICATIONS
1/ Composition pharmaceutique pour la libération programmée de dexfenfiuramine caractérisée en ce qu'elle contient des minigranules à libération rapide et des minigranules à libération lente.1 / Pharmaceutical composition for the programmed release of dexfenfiuramine characterized in that it contains rapid-release minigranules and slow-release minigranules.
2/ Composition pharmaceutique selon la revendication 1 caractérisée en ce que les minigranules à libération rapide sont constitués de supports neutres sur lesquels la dexfenfiuramine est déposée et les minigranules à libération lente sont constitués de support neutres recouverts de dexfenfiuramine et de talc enrobés par un polymère permettant la libération contrôlée de principe actif et par un agent tensioactif.2 / A pharmaceutical composition according to claim 1 characterized in that the quick-release minigranules consist of neutral supports on which the dexfenfiuramine is deposited and the slow-release minigranules consist of neutral supports coated with dexfenfiuramine and talc coated with a polymer allowing controlled release of active ingredient and by a surfactant.
3/ Composition pharmaceutique selon la revendication 2 caractérisée en ce que les minigranules à libération rapides sont enrobés par un polymère permettant une libération rapide du principe actif.3 / Pharmaceutical composition according to claim 2 characterized in that the rapid release minigranules are coated with a polymer allowing rapid release of the active principle.
4/ Composition pharmaceutique selon la revendication 2 caractérisée en ce que le polymère enrobant les minigranules à libération lente est un dérivé de cellulose ou un copoly acrylique.4 / Pharmaceutical composition according to claim 2 characterized in that the polymer coating the slow release minigranules is a cellulose derivative or an acrylic copoly.
5/ Composition pharmaceutique selon la revendication 4 caractérisée en ce que le polymère est l'éthylcellulose.5 / A pharmaceutical composition according to claim 4 characterized in that the polymer is ethylcellulose.
6/ Composition pharmaceutique selon la revendication 2 caractérisée en ce que l'agent tensioactif enrobant les minigranules à libération lente est un sel d'ester d'alcool gras.6 / A pharmaceutical composition according to claim 2 characterized in that the surfactant coating the slow release minigranules is a fatty alcohol ester salt.
Il Composition pharmaceutique selon la revendication 6 caractérisée en ce que le sel de sodium d'ester d'alcool gras est le laurylsulfate de sodium.Il Pharmaceutical composition according to claim 6 characterized in that the sodium salt of fatty alcohol ester is sodium lauryl sulfate.
8/ Composition pharmaceutique selon la revendication 2 caractérisée en ce que les minigranules à libération lente contiennent dans leur enrobage un plastifiant.8 / A pharmaceutical composition according to claim 2 characterized in that the slow release minigranules contain in their coating a plasticizer.
9/ Composition pharmaceutique selon la revendication 8 caractérisée en ce que le plastifiant est racétyltributylcitrate .9 / Pharmaceutical composition according to claim 8 characterized in that the plasticizer is racétyltributylcitrate.
10/ Composition pharmaceutique selon la revendication 2 caractérisée en ce que les minigranules à libération lente contiennent dans leur enrobage un stabilisant. 11/ Composition pharmaceutique selon la revendication 10 caractérisée en ce que le stabilisant est l'alcool cétylique.10 / A pharmaceutical composition according to claim 2 characterized in that the slow release minigranules contain in their coating a stabilizer. 11 / Pharmaceutical composition according to claim 10 characterized in that the stabilizer is cetyl alcohol.
12/ Composition pharmaceutique selon la revendication 2 caractérisée en ce que les supports neutres sont des microgranules neutres saccharose-amidon.12 / A pharmaceutical composition according to claim 2 characterized in that the neutral supports are neutral sucrose-starch microgranules.
13/ Composition pharmaceutique selon la revendication 1 caractérisée en ce que cette compositon se présente sous la forme d'une gélule.13 / Pharmaceutical composition according to claim 1 characterized in that this composition is in the form of a capsule.
14/ Composition pharmaceutique selon la revendication 1 caractérisée en ce que les minigranules sont fabriquées par montage suivi ou non d'un enrobage.14 / Pharmaceutical composition according to claim 1 characterized in that the minigranules are manufactured by mounting followed or not by a coating.
15/ Composition pharmaceutique selon la revendication 1 caractérisée en ce qu'elle permet d'obtenir deux pics de concentration plasmatique de dexfenfiuramine échelonnés dans le temps.15 / A pharmaceutical composition according to claim 1 characterized in that it allows to obtain two peaks of plasma concentration of dexfenfiuramine staggered over time.
16/ Compositions pharmaceutiques selon la revendication 2 caractérisée en ce que :16 / Pharmaceutical compositions according to claim 2 characterized in that:
- les minigranules rapides contiennent entre 10 et 80 % de dexfenfiuramine,- rapid minigranules contain between 10 and 80% dexfenfiuramine,
- les minigranules lents contiennent entre 10 et 80 % de dexfenfiuramine,- slow minigranules contain between 10 and 80% dexfenfiuramine,
- le pourcentage de talc contenu dans les minigranules à libération lente est compris entre 10 et 80 % de la masse de principe actif,the percentage of talc contained in the slow-release minigranules is between 10 and 80% of the mass of active principle,
- le pourcentage d'agent tensioactif contenu dans les minigranules à libération lente est compris entre 0,05 % et 3 % de la masse totale des minigranules avant enrobage,the percentage of surfactant contained in the slow-release minigranules is between 0.05% and 3% of the total mass of the minigranules before coating,
- le pourcentage du polymère utilisé pour l'enrobage des minigranules à libération lente est compris entre 3 et 20 % de la masse totale des minigranules avant enrobage.the percentage of the polymer used for coating the slow-release minigranules is between 3 and 20% of the total mass of the minigranules before coating.
17/ Composition pharmaceutique selon la revendication 1 utile dans le traitement de l'obésité. 17 / Pharmaceutical composition according to claim 1 useful in the treatment of obesity.
EP98912553A 1997-02-28 1998-02-26 Pharmaceutical composition for the programmed release of dexfenfluramine Withdrawn EP0975339A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9702446A FR2760190B1 (en) 1997-02-28 1997-02-28 PHARMACEUTICAL COMPOSITION FOR THE PROGRAMMED RELEASE OF DEXFENFLURAMINE
FR9702446 1997-02-28
PCT/FR1998/000377 WO1998037876A1 (en) 1997-02-28 1998-02-26 Pharmaceutical composition for the programmed release of dexfenfluramine

Publications (1)

Publication Number Publication Date
EP0975339A1 true EP0975339A1 (en) 2000-02-02

Family

ID=9504315

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98912553A Withdrawn EP0975339A1 (en) 1997-02-28 1998-02-26 Pharmaceutical composition for the programmed release of dexfenfluramine

Country Status (14)

Country Link
US (1) US5980952A (en)
EP (1) EP0975339A1 (en)
JP (1) JP2001513100A (en)
CN (1) CN1248913A (en)
AU (1) AU727614B2 (en)
BR (1) BR9807278A (en)
CA (1) CA2280980A1 (en)
FR (1) FR2760190B1 (en)
HU (1) HUP0001234A3 (en)
NO (1) NO994140L (en)
NZ (1) NZ337208A (en)
PL (1) PL335374A1 (en)
WO (1) WO1998037876A1 (en)
ZA (1) ZA981679B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2760190B1 (en) * 1997-02-28 1999-04-09 Adir PHARMACEUTICAL COMPOSITION FOR THE PROGRAMMED RELEASE OF DEXFENFLURAMINE
US7244765B2 (en) * 2004-06-25 2007-07-17 Cytokine Pharmasciences, Inc Guanylhydrazone salts, compositions, processes of making and methods of using

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2738303A (en) * 1952-07-18 1956-03-13 Smith Kline French Lab Sympathomimetic preparation
US3520975A (en) * 1967-11-27 1970-07-21 Robins Co Inc A H Anorexigenic compositions comprising fenfluramine and scopolamine
FR2183546B1 (en) * 1972-05-10 1975-06-20 Servier Lab
US4452815A (en) * 1980-06-16 1984-06-05 Massachusetts Institute Of Technology Method of utilizing d,l-fenfluramine for modifying feeding behavior
US4309445A (en) * 1980-06-16 1982-01-05 Massachusetts Institute Of Technology d-Fenfluramine for modifying feeding behavior
US4728512A (en) * 1985-05-06 1988-03-01 American Home Products Corporation Formulations providing three distinct releases
GB8519310D0 (en) * 1985-07-31 1985-09-04 Zyma Sa Granular active substances
US4649161A (en) * 1986-06-16 1987-03-10 Massachusetts Institute Of Technology Method for treating depression with d-fenfluramine
EP0308317A1 (en) * 1987-09-14 1989-03-22 Sanofi Chewable anorectic composition and process to prepare it
US5258186A (en) * 1989-03-10 1993-11-02 Yamanouchi Pharmaceutical Co., Ltd. Drug release controlling coating material for long acting formulations
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5084287A (en) * 1990-03-15 1992-01-28 Warner-Lambert Company Pharmaceutically useful micropellets with a drug-coated core and controlled-release polymeric coat
FR2663539B1 (en) * 1990-06-22 1994-10-07 Adir USE OF D-FENFLURAMINE FOR OBTAINING MEDICINES FOR THE TREATMENT OF IMMUNE DEFICIENCIES IN THE AGED SUBJECT.
FR2677886B1 (en) * 1991-06-18 1995-03-31 Adir MATRIX TABLET FOR THE EXTENDED RELEASE OF INDAPAMIDE AFTER ORAL ADMINISTRATION.
US5213811A (en) * 1991-09-13 1993-05-25 Sterling Drug Inc. Oral sustained-release drug compositions
CA2124568C (en) * 1992-10-09 2003-11-11 Yoshiaki Yano Method for producing microgranulated particle
EP0710106A4 (en) * 1993-03-17 1999-07-21 Pietr Hitzig Method of treating addictive behaviors
US5502080A (en) * 1994-11-01 1996-03-26 Hitzig; Pietr Combined use of dopamine and serotonin agonists in the treatment of allergic disorders
FR2760190B1 (en) * 1997-02-28 1999-04-09 Adir PHARMACEUTICAL COMPOSITION FOR THE PROGRAMMED RELEASE OF DEXFENFLURAMINE

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9837876A1 *

Also Published As

Publication number Publication date
FR2760190A1 (en) 1998-09-04
AU6734698A (en) 1998-09-18
NZ337208A (en) 2000-08-25
FR2760190B1 (en) 1999-04-09
PL335374A1 (en) 2000-04-25
AU727614B2 (en) 2000-12-14
JP2001513100A (en) 2001-08-28
US5980952A (en) 1999-11-09
NO994140L (en) 1999-10-28
ZA981679B (en) 1998-08-24
CN1248913A (en) 2000-03-29
BR9807278A (en) 2000-05-23
NO994140D0 (en) 1999-08-26
HUP0001234A2 (en) 2001-06-28
CA2280980A1 (en) 1998-09-03
WO1998037876A1 (en) 1998-09-03
HUP0001234A3 (en) 2001-07-30

Similar Documents

Publication Publication Date Title
EP0939626B1 (en) Galenic formula with extended release of milnacipran
EP0385846B1 (en) Sustained-release pharmaceutical composition containing valproic acid
EP1194125B1 (en) Method for making granules with masked taste and instant release of the active agent
EP0217778B1 (en) Galenical forms for the sustained release of verapamil, their preparation and medicaments containing them
CA2652023C (en) New form of administration of racecadotril
FR2624732A1 (en) SUSTAINED RELEASE PHARMACEUTICAL FORMULATION
EP2568974A1 (en) Alcohol-resistant oral pharmaceutical form
EP1126829B1 (en) Particles coated with granulated crystalline ibuprofen
EP0830129B1 (en) Solid compositions containing polyethyleneoxide and a non-amorphous active principle
EP2349227A2 (en) Alcohol-resistant tablet
EP0216743B1 (en) Galenical forms of verapamil, preparation thereof and medicaments containing them
EP1365751A2 (en) Granules and granules coated with a masked taste
EP1646379A2 (en) Novel solid pharmaceutical composition comprising amisulpride
EP0868184A1 (en) Sustained-release microgranules containing diltiazem as the active principle
CA2545139A1 (en) Low-dose tablets having a network of polymers
EP0975339A1 (en) Pharmaceutical composition for the programmed release of dexfenfluramine
JPH09512023A (en) Ranitidine tablet having hydroxypropylmethylcellulose-containing coating and method for producing the coating
BE900824A (en) COMPOSITION OF TABLETS.
EP0739201B1 (en) Microgranules of 5-nitro imidazole derivatives
BE1000087A3 (en) PHARMACEUTICAL COMPOSITION CONTAINING vinburnine AND METHOD OF PREPARATION.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990810

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: LES LABORATOIRES SERVIER

RBV Designated contracting states (corrected)

Designated state(s): AT BE CH DE DK ES FI LI

RBV Designated contracting states (corrected)

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RBV Designated contracting states (corrected)

Designated state(s): AT BE CH DE DK ES FI LI

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040622